石杉碱丙 | 147416-32-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 石杉碱丙
• 英文名称: Huperzine C
• 英文别名: (1R,9R,13R)-1-amino-13-ethenyl-11-methyl-6-azatricyclo[7.3.1.02,7]trideca-2(7),3,10-trien-5-one
• CAS: 147416-32-8
• 化学式: C₁₅H₁₈N₂O
• 分子量: 242.32
• InChiKey: IZGRHSRWTILCID-FIXISWKDSA-N

物化性质

• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Use of higher doses of modified release huperzine formulations
  申请人：SUPERNUS PHARMACEUTICALS, INC.

  公开号：US11351120B2

  公开（公告）日：2022-06-07

  The present application discloses pharmaceutical compositions and methods of treating neurological disorders and seizure disorders with the high dose modified release compositions of huperzine. The pharmaceutical compositions and methods described herein, allow for higher dosing of huperzine, while avoiding rapid peak plasma levels, thereby avoiding the dose-limiting adverse events associated with the immediate release formulations.

  本申请公开了使用高剂量改良释放组合物治疗神经系统疾病和癫痫发作的药物组合物和方法。本文所述的药物组合物和方法可以提高胡朴素的剂量，同时避免血浆水平迅速达到峰值，从而避免了与速释制剂相关的剂量限制性不良事件。
• COMPOSITIONS AND METHODS FOR USING HUPERZINE AND ANALOGS THEREOF
  申请人：INSERO HEALTH INC.

  公开号：US20150335624A1

  公开（公告）日：2015-11-26

  A method of treating a seizure disorder is described wherein an acetylcholinesterase(AChE) inhibitor is administered to a subject having a seizure disorder and an increased risk of a cardiac event from the seizure disorder, wherein the AChE inhibitor decreases the risk of such cardiac event. Further described are methods of decreasing the risk of a cardiac event in subjects with or without a seizure disorder by administering a therapeutically effective amount of an AChE inhibitor. Methods of treating kidney disease and reducing an elevated CRP level by administering an AChE inhibitor are also described.
• USE OF HIGHER DOSES OF MODIFIED RELEASE HUPERZINE FORMULATIONS
  申请人：SUPERNUS PHARMACEUTICALS, INC.

  公开号：US20200155456A1

  公开（公告）日：2020-05-21

  The present application discloses pharmaceutical compositions and methods of treating neurological disorders and seizure disorders with the high dose modified release compositions of huperzine. The pharmaceutical compositions and methods described herein, allow for higher dosing of huperzine, while avoiding rapid peak plasma levels, thereby avoiding the dose-limiting adverse events associated with the immediate release formulations.
• MODIFIED RELEASE PHARMACEUTICAL COMPOSITIONS OF HUPERZINE AND METHODS OF USING THE SAME
  申请人：Biscayne Neurotherapeutics, Inc.

  公开号：US20210353552A1

  公开（公告）日：2021-11-18

  The present application discloses pharmaceutical compositions for modified release of huperzine. The pharmaceutical compositions and methods described herein, allow for dosing of huperzine at higher therapeutic thresholds, while avoiding rapid serum peak plasma levels, thereby avoiding the adverse nausea and vomiting associated with the immediate release pharmaceutical compositions. Methods of treating neurological disorders and/or seizure disorders with the modified release compositions is also described.